Invivyd Says Pemivibart Confers 84% Reduction In COVID-19 Risk, To Engage FDA With Expedited Pathway

Invivyd's CANOPY phase 3 trial showed Pemivibart conferred an 84% reduction in the risk of symptomatic COVID-19 over six months, compared to placebo, with a further six months of follow up. The company plans to engage the FDA on an expedited pathway for scalable COVID-19 prevention and treatment options, particularly as the FDA has acknowledged uncertainty around repeat COVID-19 vaccine booster efficacy. Pemgarda (pemivibart) is a monoclonal antibody demonstrating in vitro neutralizing activity against major SARS-CoV-2 variants.

Analysis

Invivyd, Inc. (IVVD) reported highly positive results from its CANOPY phase 3 trial, demonstrating that its investigational monoclonal antibody, Pemivibart (Pemgarda), achieved an 84 percent reduction in the risk of symptomatic COVID-19 over a six-month period compared to placebo. This development is particularly significant given the U.S. Food and Drug Administration's (FDA) recent acknowledgment of uncertainty surrounding the benefits of repeated COVID-19 vaccine boosters. Invivyd intends to leverage these strong clinical outcomes by engaging with the FDA to discuss an expedited pathway for Pemgarda, aiming to develop scalable COVID-19 prevention and treatment solutions. The CANOPY trial's cohort comprised average Americans at risk of SARS-CoV-2 acquisition in typical indoor settings, enhancing the real-world applicability of the findings. Furthermore, Pemgarda has shown in vitro neutralizing activity against major SARS-CoV-2 variants by targeting the spike protein's receptor binding domain, potentially offering a durable defense mechanism as the virus evolves. This confluence of positive trial data and a shifting perspective on vaccine booster efficacy positions Invivyd favorably in addressing an ongoing public health need.

Key Decisions for Investors

• Investors should closely monitor Invivyd's forthcoming discussions with the FDA regarding an expedited regulatory pathway for Pemgarda, as successful negotiation could significantly de-risk and accelerate its commercialization timeline.
• The compelling 84% risk reduction demonstrated by Pemivibart, juxtaposed with the FDA's questioning of repeat vaccine booster efficacy, suggests a potentially substantial market opportunity for IVVD, which may not be fully priced into the stock.
• Consider the strong positive sentiment (0.8 for IVVD) and optimistic tone surrounding this announcement, but also factor in the inherent risks associated with biopharmaceutical drug development, including future variant emergence and regulatory hurdles, when evaluating positions in IVVD.